Clinical Trials
24 trialsNCT02973789 2026-03-18
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Phase 3 Completed
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT05348668 2026-01-07
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Anhui Provincial Hospital
Phase 2 Completed
NCT05440916 2025-12-02
PRIMM
University Medical Centre Maribor
Phase 2 Completed
NCT04417465 2025-09-25
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
AbbVie
Phase 1 Completed
NCT04681131 2025-09-25
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
BioAtla, Inc.
Phase 2 Completed
NCT03425279 2025-09-23
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
Phase 1/2 Completed
NCT05509699 2025-08-29
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT03984357 2025-07-17
PLATINUM
Sun Yat-sen University
Phase 2 Completed
NCT06991907 2025-05-28
PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety
Jiangxi Provincial Cancer Hospital
Phase NA Completed
NCT04997382 2025-02-25
CLASSIC5
Hunan Province Tumor Hospital
Phase 2 Completed
NCT03504488 2025-01-15
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Phase 1/2 Completed
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT03879512 2024-09-19
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
Phase 1/2 Completed
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT03989336 2024-07-15
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Chinese PLA General Hospital
Phase 2 Completed
NCT03817736 2024-05-09
START-FIT
The University of Hong Kong
Phase 2 Completed
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT04944888 2023-12-19
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Chinese PLA General Hospital
Phase 1 Completed
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT03790488 2023-07-03
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Jounce Therapeutics, Inc.
Phase 1 Completed
NCT02574533 2017-09-27
Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma
Gradalis, Inc.
Phase 1 Completed